NASDAQ
GANX

Gain Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Gain Therapeutics Inc Stock Price

Vitals

Today's Low:
$3.64
Today's High:
$3.9118
Open Price:
$3.82
52W Low:
$2.8
52W High:
$6.19
Prev. Close:
$3.66
Volume:
30534

Company Statistics

Market Cap.:
$42.54 million
Book Value:
0.878
Revenue TTM:
$55180
Operating Margin TTM:
-40364.41%
Gross Profit TTM:
$-7660886
Profit Margin:
0%
Return on Assets TTM:
-55.52%
Return on Equity TTM:
-115.76%

Company Profile

Gain Therapeutics Inc had its IPO on 2021-03-18 under the ticker symbol GANX.

The company operates in the Healthcare sector and Biotechnology industry. Gain Therapeutics Inc has a staff strength of 28 employees.

Stock update

Shares of Gain Therapeutics Inc opened at $3.82 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.64 - $3.91, and closed at $3.64.

This is a -0.55% slip from the previous day's closing price.

A total volume of 30,534 shares were traded at the close of the day’s session.

In the last one week, shares of Gain Therapeutics Inc have increased by +8.66%.

Gain Therapeutics Inc's Key Ratios

Gain Therapeutics Inc has a market cap of $42.54 million, indicating a price to book ratio of 1.636 and a price to sales ratio of 210.9717.

In the last 12-months Gain Therapeutics Inc’s revenue was $55180 with a gross profit of $-7660886 and an EBITDA of $-22203662. The EBITDA ratio measures Gain Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Gain Therapeutics Inc’s operating margin was -40364.41% while its return on assets stood at -55.52% with a return of equity of -115.76%.

In Q2, Gain Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 47%.

Gain Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gain Therapeutics Inc’s profitability.

Gain Therapeutics Inc stock is trading at a EV to sales ratio of 85.1787 and a EV to EBITDA ratio of -0.9537. Its price to sales ratio in the trailing 12-months stood at 210.9717.

Gain Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.26 million
Total Liabilities
$5.59 million
Operating Cash Flow
$3.05 million
Capital Expenditure
$3644
Dividend Payout Ratio
0%

Gain Therapeutics Inc ended 2024 with $18.26 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.26 million while shareholder equity stood at $11.09 million.

Gain Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $5.59 million in other current liabilities, 1263.00 in common stock, $-51341485.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.32 million and cash and short-term investments were $16.19 million. The company’s total short-term debt was $347,434 while long-term debt stood at $466638.00.

Gain Therapeutics Inc’s total current assets stands at $17.31 million while long-term investments were $0.00 and short-term investments were $9.87 million. Its net receivables were $160730.00 compared to accounts payable of $924390.00 and inventory worth $-160730.00.

In 2024, Gain Therapeutics Inc's operating cash flow was $3.05 million while its capital expenditure stood at $3644.

Comparatively, Gain Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$3.64
52-Week High
$6.19
52-Week Low
$2.8
Analyst Target Price
$9

Gain Therapeutics Inc stock is currently trading at $3.64 per share. It touched a 52-week high of $6.19 and a 52-week low of $6.19. Analysts tracking the stock have a 12-month average target price of $9.

Its 50-day moving average was $3.9 and 200-day moving average was $4.15 The short ratio stood at 4.04 indicating a short percent outstanding of 0%.

Around 2082.3% of the company’s stock are held by insiders while 1041% are held by institutions.

Frequently Asked Questions About Gain Therapeutics Inc

The stock symbol (also called stock or share ticker) of Gain Therapeutics Inc is GANX

The IPO of Gain Therapeutics Inc took place on 2021-03-18

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.15
0.02
+13.85%
$1234.1
-53.5
-4.16%
$0.46
0.01
+1.78%
Rolex Rings Limited (ROLEXRINGS)
$2287.75
-75.85
-3.21%
Aptech Limited (APTECHT)
$288
-18.05
-5.9%
Paychex Inc (PAYX)
$119.76
-0.13
-0.11%
$28.05
0.11
+0.39%
$401.8
-18.2
-4.33%
$0.17
0.02
+12.67%
$3580.6
101.25
+2.91%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson’s disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Address

4800 Montgomery Lane, Bethesda, MD, United States, 20814